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Abstract 
Microbial metabolism of carnitine to 
trimethylamine (TMA) in the gut can 
accelerate atherosclerosis and heart 
disease and these TMA-producing 
enzymes are therefore important drug 
targets. Here, we report the first structures 
of the carnitine oxygenase CntA, an 
enzyme of the Rieske oxygenase family. 
CntA exists in a head-to-tail 3 trimeric 
structure. The two functional domains (the 
Rieske and the catalytic mononuclear iron 
domains) are located > 40 Å apart in the 
same monomer but adjacent in two 
neighbouring monomers. Structural 
determination of CntA and subsequent 
electron paramagnetic resonance 
measurements uncover the molecular 
basis of the so-called bridging glutamate 
(E205) residue in inter-subunit electron 
transfer. The structures of the substrate-
bound CntA help to define the substrate 
pocket. Importantly, a tyrosine residue 
(Y203) is essential for ligand recognition 
through a π-cation interaction with the 
quaternary ammonium group. This 
interaction between an aromatic residue 
and quaternary amine substrates allows us 
to delineate a subgroup of Rieske 
oxygenases (group V) from the prototype 
ring-hydroxylating Rieske oxygenases 
involved in bioremediation of aromatic 
pollutants in the environment. 
Furthermore, we report the discovery of 
the first known CntA inhibitors and solve 
the structure of CntA in complex with the 
inhibitor, demonstrating the pivotal role of 
Y203 through a π-π stacking interaction 
with the inhibitor. Our study provides the 
structural and molecular basis for future 
discovery of drugs targeting this TMA-
producing enzyme in human gut.  
 
Introduction  
The vast array of co-habiting 
microorganisms in the human gut impose 
a discernible influence on human 
wellbeing and disease states. There is a 
considerable interest in the past decade to 
investigate the formation of methylated 
amines in human health, particularly with 
regard to cardiovascular diseases and non-
alcoholic fatty liver diseases (1-5). Dietary 
intake of quaternary amines such as 
choline and carnitine, both of which are 
prevalent in the human diet, can be 
processed by gut microbiota to produce 
small methylated amines (e.g. 
trimethylamine, TMA), which enter 
vascular circulation leading to subsequent 
hepatic oxidation to trimethylamine oxide 
(TMAO). TMAO is linked to cardiovascular 
disease, kidney disease, diabetes and 
various forms of cancers (6-8). These TMA-
producing and metabolising enzymes from 
gut microbiota therefore represent 
promising new drug targets (9-11).  
 
The key microbial enzymes responsible for 
TMA formation from choline and carnitine 
have only been identified relatively 
recently (12-14). Choline-TMA lyases 
belong to a large family of proteins, 
attacking the carbon-nitrogen (C-N) bond 
in choline using a radical species generated 
from a conserved glycine residue. The 
structure of choline-TMA lyase CutC has 
been solved recently (16-17), aiding the 
development of inhibitors (substrate 
analogues) for attenuating TMA formation 
from choline (18-21). The carnitine 
monooxygenase (CntA) and associated 
reductase (CntB) responsible for carnitine 
oxidation to TMA (Figure 1A) was originally 
identified in Acinetobacter spp. but was 
subsequently found to be present in a 
range of gut microbiota species (13-15). 
CntA belongs to a large group of non-heme 
iron-containing Rieske oxygenase family 
(13). Rieske oxygenases are typically 
multicomponent enzyme systems 
involving an oxygenase, a reductase and 
sometimes a separate flavin cofactor (22). 
The oxygenase component has a 
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 3 
conserved [2Fe-2S] Rieske centre 
coordinated by two cysteine and two 
histidine residues and a catalytic 
mononuclear iron (Fe) centre (23-24). A 
reductase component reduces pyridine 
nucleotides, generating electrons which 
are ultimately transferred to the Rieske 
oxygenase for substrate oxidation. The 
archetypal Rieske oxygenases, also known 
as ring-hydroxylating Rieske oxygenases, 
catalyse the oxidation of a range of 
aromatic and polyaromatic substrates; as 
such, they are important in bioremediation 
of environmental pollutants (24-25). 
Structural determination of several ring-
hydroxylating Rieske oxygenases (e.g. 
naphthalene dioxygenase and biphenyl 
dioxygenase) reveals that the Rieske 
centre and the catalytic mononuclear Fe 
centre are usually far apart in the same 
subunit (>40 Å) and effective electron 
transfer can only occur across the interface 
of two neighbouring subunits (23, 26, 27).  
 
It has becoming increasingly clear that 
quaternary amines-oxidising Rieske 
oxygenases represent a new emerging 
clade of the Rieske oxygenases family that 
is distinct from the archetypal ring-
hydroxylating aromatic Rieske oxygenases 
(13, 27-29). The carnitine-degrading CntA 
enzyme is a promising new drug target, 
given that gut microbial metabolism of 
carnitine is known to increase plasma 
TMAO, leading to the subsequent 
development of atherosclerosis and 
cardiovascular diseases (9). However, no 
structure of CntA or description of possible 
inhibitors have been published. In this 
study, we report high-resolution crystal 
structures of CntA with and without 
substrates-bound and report the first 
known inhibitors for this enzyme and the 
crystal structure of an inhibitor-bound 
CntA. Structure, biochemical and electron 
paramagnetic resonance (EPR) 
characterisation CntA and mutants 
provides novel insights into the mode of 
inhibition and the inter-/intra- subunit 
electron transfer in carnitine oxidation. 
Our work therefore provides the structural 
and molecular basis for future discovery of 
drugs targeting this TMA-producing 
enzyme in human gut.  
 
Results 
Structure determination of CntA  
We set out to solve the structure of CntA 
from A. baumannii and we successfully 
obtained structures of CntA in the apo 
protein form (2.1 Å, PDB 6Y8J) and ligand-
bound forms with two substrates, carnitine 
(2.0 Å, PDB 6Y9D) and -butyrobetaine 
((gBB), 1.6 Å, PDB 6Y8S) (Table 1). We 
observed a head-to-tail 3 trimeric 
structure for CntA (Figure 1B), with the 
Rieske [2Fe-2S] cluster and mononuclear 
Fe centre at opposing regions of the 
monomer 44 Å apart (Figure 1C). The 
observed assembly of 3 homotrimer is in 
agreement with the analyses by native 
protein gel (13) and analytic gel filtration 
(Figure S1). The two CntA substrate bound 
structures and apo form are 
superimposable with an average root-
mean-square deviation (rmsd) of 0.487 Å 
(Table S1).  
  For all three structures, the Rieske 
[2Fe-2S] cluster is well-defined and 
coordinated by two histidine and two 
cysteine residues (Figure 1D, Figure S2A). 
This Rieske centre is structurally conserved 
in all Rieske oxygenases, such as 
stachydrine demethylase Stc2 (28), 
naphthalene 1,2-dioxygenase NdoB (26) 
and dicamba monooxygenase DdmC (30) 
(Figure S2B). The active sites containing 
mononuclear Fe centres are, however, 
considerably varied in enzymes of the 
Rieske oxygenase family (Figure S2B), 
reflecting the diverse catalytic reactions 
catalysed by these enzymes. The 
mononuclear Fe exists in an octahedral 
geometry and is coordinated by two 
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 4 
histidine ligands (His 213, His 208) and a 
bidentate aspartate residue (Asp 323) in a 
well-documented His-His-Asp catalytic 
triad (31), co-ordinating one face of the Fe 
centre (Figure 1E). A pair of reduced Cys 
(Cys206, Cys209) is found near the 
mononuclear Fe in CntA whereas in 
stachydrine demethylase Stc2 the 
corresponding Cys formed a disulphide 
bridge (28). A water molecule and a 
thiocyanate [SCN]- anion occupy the two 
co-ordination sites, which are 2.2 Å and 2.3 
Å away from the mononuclear Fe centre in 
CntA, respectively (Figure 1E, Figure S2C). 
Both the water molecule and [SCN]- are 
positioned 3.7 Å below the C adjacent to 
the carnitine ammonium group, which is 
expected to be the site of hydroxylation 
catalysed by this enzyme (Figure 1E). SCN-
bound at the O2 site likely resulted in the 
stabilisation of CntA co-crystalized with the 
substrates. The catalytic mononuclear Fe 
in purified CntA is in a ferrous (Fe2+) state, 
showing no EPR signals associated with 
either high-spin (S = 5/2) or low-spin (S = ½) 
ferric centre (Fe3+) despite purifying the 
protein under aerobic conditions. This is 
confirmed by the addition of nitric oxide 
(NO) to CntA, showing an EPR signal from a 
S = ½ species of the Fe2+-NO adduct (Figure 
1F).  This is contrast to the other non-heme 
oxygenase enzymes, where NO binding to 
the mononuclear iron centre often led to 
the formation of high-spin, S = 3/2 signal 
(32). This plausibly suggests that the 
mononuclear iron ion exists as an S = 0 in 
its ferrous state. The observed EPR signal 
for the Fe2+-NO adduct is similar to the 
previously reported heme/non-heme-NO 
adducts (33-34). 
 
Structural basis of long-distance electron 
transfer and EPR spectroscopy  
Structural determination of CntA revealed 
that the two functional domains in CntA 
(the Rieske domain and the catalytic 
mononuclear Fe domain) are located 44 Å 
apart in the same subunit. As such, 
electron transfer to the catalytic 
mononuclear Fe centre is likely to occur 
only at the interface of two adjacent CntA 
subunits (12.2 Å apart) and facilitated by 
the so-called bridging glutamate (E205, 
Figure 2A) (13). Electron transfer from 
NADH to the carnitine oxygenase CntA is 
mediate through an flavin mononucleotide 
(FMN)-containing reductase CntB, which 
was essential for the enzyme activity (13). 
To monitor electron transfer pathway 
(Figure 2B) from the reductant NADH via 
the flavin-containing reductase CntB to the 
catalytic domain in the oxygenase CntA, 
continuous wave (cw)-EPR was used.  
Purified CntB is EPR-silent (Figure 
2C, black trace); however, the reduced 
ferredoxin-centre in CntB is readily 
detectable once NADH is added (red trace). 
The EPR spectrum of reduced CntB has a 
characteristic reduced ferredoxin [2Fe-
2S]+1 signal [g tensor 2.031, 1.937, 1.899] 
and a radical signal resulted from flavin 
semiquinone gave=2.0015. Similar flavin 
semiquinone radicals have been observed 
previously in other Rieske oxygenase 
reductase as well as monoamine oxidase 
(35, 36). Reduced CntB spectrum was 
simulated by combination of two different 
S = ½ spin states (97 % for the reduced 
ferredoxin and 3 % for a flavin 
semiquinone radical) (Table 2), confirming 
electron transfer from the reductant NADH 
to the ferredoxin domain in CntB (steps 1-
3 in Figure 2B). The purified CntA (blue 
trace) showed a very weak anisotropic EPR 
signal with gave < 2.0 [g tensor 2.011, 1.916, 
1.757], indicating that the Rieske centre in 
CntA is predominantly in the oxidized, 
diferric [2Fe-2S]2+ state (Table 2) (37-38). 
Addition of an oxidizing agent (H2O2) to 
CntA has minimal effect on the overall 
spectrum (Figure S3A), however, the 
Rieske centre in CntA can be readily 
reduced by dithionite (Figure S3B). CntA 
also appears capable of oxidising the 
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 5 
substrate (carnitine) using H2O2 in the 
absence of CntB/NADH (Figure S3A), 
consistent with the peroxide shunt-
mechanism known in other Rieske 
oxygenases (39-40). In order to monitor 
electron flow from CntB to CntA, the 
spectrum of CntA +NADH+CntB was 
recorded (magenta trace). This complex 
spectrum can be simulated by the 
combination of three different S = ½ spin 
states (Table 2, Figures S4). Thus, the 
addition of CntB+NADH to CntA allowed 
reduction of the Rieske centre in CntA, 
confirming cross-subunit electron transfer 
from CntB to CntA (step 4 in Figure 2B). 
We next sought to confirm the 
electron flow from the reduced Rieske 
cluster to the catalytic mononuclear Fe 
centre in CntA and investigate the critical 
role of the bridging E205 in electron 
transfer as suggested by the CntA structure 
(step 5 in Figure 2B). The E205 residue 
bridges the Rieske cluster on one subunit 
and the mononuclear Fe centre in the 
adjacent subunit (Figure 2A) (13, 41). None 
of the E205 mutants that we generated in 
this study were active (Figure 2D), with no 
major perturbations to the overall 
secondary structure as observed by 
circular dichroism (Figure 2E). As it is 
known that substrate-binding can be 
required for the activation of the catalytic 
mononuclear Fe centre to initiate catalysis 
(42-43), the substrate (carnitine) was 
added to the reaction and the EPR 
spectrum was monitored (Figure 2C, cyan 
trace). The spectrum shows no EPR signals 
at low magnetic fields, ruling out the 
presence of high-spin (S = 5/2 or 3/2) ferric 
species in the sample. However, strong 
isotropic (3350 G) and highly anisotropic 
EPR signals are observed between the 
magnetic fields of 3200-3900 G (Figure 2C). 
The observed gave < 2.0 (Table 2) strongly 
indicates that these EPR transitions likely 
arise predominantly from one-electron 
reduced [2Fe-2S]+1 Rieske cluster in CntA 
and the isotropic signal at 3350 G is likely 
originated from a new organic radical 
species, which is formed during CntA 
catalysis in the presence of the substrate. 
The EPR simulation from these two S = ½ 
species (reduced Rieske cluster and a new 
organic radical species) reproduced the 
observed spectra (Table 2, Figure S4). The 
complete loss of reduced ferredoxin EPR 
signal from CntB, together with the 
formation of a novel organic radical species 
(isotropic signal seen at 3350 G) in 
CntA+CntB+NADH+carnitine suggests an 
efficient electron transfer to the catalytic 
mononuclear Fe in the wild-type CntA 
(step 5 in Figure 2B). 
To further support this proposed 
electron transfer pathway, we compared 
EPR spectra of the E205A mutant with the 
wild-type CntA. Indeed, the EPR spectra 
are significantly different between E205A 
(Figure 2C, purple trace) and the wild-type 
CntA (cyan trace). The spectrum of the 
E205A mutant shows complex EPR signals 
with 4 different S = ½, EPR active species 
(Table 2). In the spectrum with the E205A 
mutant, a significant amount (60 %) of the 
EPR signal of the reduced [2Fe-2S]1+ 
ferredoxin in CntB was observed while this 
was not found in the spectrum of the wild-
type CntA, suggesting that electron flow is 
significantly impacted in this mutant. 
Together, the EPR observations provide 
strong evidence of each step involved in 
the electron flow as proposed in Figure 2B 
and confirm the role of the bridging 
glutamate (E205) in cross-subunit electron 
transfer as suggested by the CntA 
structure.  
 
Structural basis of substrate binding and 
inhibition  
CntA can catalyse the oxidation of carnitine 
and several substrate analogues (Figure 
3A). The high resolution CntA structures 
co-crystalized with the ligands (carnitine, 
2.0 Å; gBB, 1.6 Å) allowed us to define the 
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 6 
substrate binding pockets. The ligands 
were built into the clear density which was 
much better defined for the carnitine 
structure (Figure 3B). The substrate-
binding site is formed by a series of -
sheets and two -helices coordinating the 
substrate through hydrophobic/steric 
interactions involving residues Phe 258, 
Tyr 315, and Phe 319 and polar 
interactions with residues Tyr 225, Asn 
270, and Tyr 295. (Figure 3C, Figure S5). 
The Phe 319 residue is positioned at the 
kink of an observed -helix feature for 
residues 306 to 337 (44). Importantly, we 
also observe that Tyr 203 forms a -cation 
interaction with the positively charged 
ammonium group in the substrates (Figure 
3C). The importance of the binding site 
residues was then tested by mutating them 
to alanine. Indeed, all mutants decreased 
or abolished activity (Figure 3D). 
Interestingly, the Y203F mutant was active 
(Figure 3D), demonstrating a recovery of 
function and the pivotal role of the -
cation interaction with the ammonium 
group.  
 The presence of an aromatic 
residue in this position (Y203 or F203) 
appears to be restricted to CntA and 
several closely related enzymes. Indeed, a 
comprehensive phylogenetic analysis of 
Rieske oxygenases, including several other 
recently defined Rieske enzymes involved 
in the oxidation of quaternary ammonium 
substrates clearly defined a group which 
delineates quaternary ammonium Rieske 
oxygenases (group V) from the well-
studied ring-hydroxylating Rieske 
oxygenases (Figure 4A) (27, 29). While 
group I-IV Rieske oxygenases primarily 
catalyse the dihydroxylation of aromatic 
and polyaromatic compounds that are 
important in bioremediation of 
environmental pollutants, group V Rieske 
oxygenases include enzymes that 
principally oxidise quaternary ammonium 
substrates (Figure 4B). Interestingly, based 
on the presence or absence of the 
signature aromatic residue at position 203 
(Y203 or F203), group V Rieske oxygenases 
can be further separated into two clades 
Va and Vb where in clade Vb the Tyr (or Phe 
in OxyBAC) is replaced by an Asn (Figure 
4C). Substrates for the former clade 
include carnitine (CntA, 13), choline 
(CmoA, CmoS, CmoB, 45-47) and 
benzalkonium (OxyBAC, 29) whereas the 
latter clade Vb enzymes undertake 
oxidative demethylation from the 
ammonium group for glycine betaine 
(GbcA, BmoA, 27) and proline betaine 
(stachydrine, Stc2, 28). 
 Comparing the ligand-bound 
structures of CntA (group Va) and Stc2 
(group Vb) uncovers striking differences in 
the way quaternary amine substrates are 
oriented (28). In Stc2 the substrate 
analogue proline is ligated with the 
catalytic Fe through the carboxylate group 
(Figure 4D), whereas in CntA, although a 
carboxylate group is present, the 
substrates were oriented via a -cation 
interaction with the trimethylammonium 
moiety and the carboxylate group is not 
ligated with the mononuclear Fe (Figure 
3C).  
 In order to understand the 
substrate specificity for the enzyme, we 
investigated the structure activity 
relationship (SAR) of 22 substrate 
analogues with differences on the aliphatic 
chain, the carboxyl group or the amine 
terminal groups (Figure 5A, Figure S6). In 
addition to carnitine/-butyrobetaine 
(compound 1 and 2), CntA can also oxidise 
meldonium (compound 3) and 1-butyl-
trimethylammonium (compound 4) albeit 
with a lower affinity (Figure 3A, Figure 5A). 
The lack of a carboxylic acid in compound 
4 reduces the affinity for the substrate and 
substrates with longer alkyl chains or other 
functional groups showed no activity 
(compounds 5-9). A further series of 
compounds related to -butyrobetaine but 
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 7 
not quaternary ammonium salts 
(compounds 10- 12) did not serve as 
substrates for CntA. Other quaternary 
amine compounds tested were not 
accepted as substrates (Figure S6). 
Together, structural, mutagenesis and SAR 
data therefore suggest that the substrates 
for CntA are primarily co-ordinated 
through a -cation interaction between 
Y203 and the trimethylammonium group, 
which positions the substrate in place 
above the mononuclear Fe site for 
oxidative cleavage to occur (Figure 5B). 
Although there is some tolerance for the 
lack of a carboxylic acid, increases in the 
length of the molecule and increased steric 
bulk are not favoured for enzyme activity 
as they likely disturb the polar interaction 
with Tyr 295.  
 
A competitive inhibitor binds to the same 
substrate recognition pocket through π-π 
stacking interactions 
Encouraged by previous success in the 
identification of substrate mimics as 
potent inhibitors for the choline-TMA lyase 
CutC (18-21), we also screened these 
carnitine analogues (Figure 5A, Figure S6) 
as potential inhibitors of CntA in 
competition assays. However, none of 
these substrate analogues inhibited CntA 
activity.  We thus used a random approach 
by screening drug libraries and successfully 
obtained 3 inhibitor compounds MMV1, 
MMV3 and MMV12 (Figure 6A). Their 
inhibitory IC50 values are in the range of 
1.1-5.8 μM (Figure 6B). From competition 
assay data (Figure S7) we were able to 
derive a Ki (1.09 μM) for MMV12 (ID, 
MMV020670), indicating that it is likely a 
competitive inhibitor.  
We successfully solved the 
structure of MMV12 with CntA (PDB, 6ZGP) 
and indeed, the inhibitor occupied the 
substrate binding pocket (Figure 6D). 
Interestingly, Tyr 203 and Tyr 295, both of 
which are important for the coordination 
of carnitine in CntA (Figure 5B), also play a 
key role in binding to the inhibitor (Figure 
S8). Tyr 203 form a π-π stacking interaction 
with the 1,6‐naphthyridine core ring and 
Tyr 295 forms polar interaction with the 
oxygen on the methoxy group in the 
inhibitor. Interestingly, the inhibitor is also 
coordinated to the mononuclear Fe via a 
nitrogen on the 1,6‐naphthyridine ring at 
distance of 2.65Å and to an oxygen of the 
carboxylic acid moiety of Asp 323 at 2.7Å 
(Figure S8). Other π-π interactions are also 
observed between Phe 319 and the phenyl 
methoxy group and between Phe 258/ Phe 
247 and the imidazole group. When the 
binding pockets of carnitine and MMV12 
are compared (Figure 6E & F), Phe 258 
moves to accommodate the imidazole 
group of the inhibitor whilst the loop 
containing Phe 216 is drawn in closer to the 
active site to form the π-π interaction with 
the inhibitor.  
The two other inhibitors MMV1 
and MMV3 share similar structural 
features to MMV12. MMV1 has a core 
bicyclic fused aromatic scaffold with two 
branching cyclic groups. MMV3 has an 
imidazole group with an aliphatic amine 
linker group. The remaining pair of 
inhibitors show more complex patterns of 
inhibition for CntA. Using the structure of 
CntA co-crystalized with MMV12, we 
applied in silico docking of MMV1 and 
MMV3 to observe if these molecules could 
adopt comparable poses (Figure S9). The 
results showed that both compounds show 
logical poses in the binding site with 
docking scores of -10.576 (kcal/mol) and -
11.169 (kcal/mol), respectively. These are 
comparable to a score of -11.7 (kcal/mol) 
when MMV12 is docked into the empty 
pocket in CntA. Both docked compounds 
demonstrate likely coordination to the Fe 
centre via a nitrogen atom and similar π-π 
stacking interactions.  
In order to assess the activity of 
these inhibitors, we monitored the impact 
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 8 
of these inhibitors on the production of 
TMA in A. baumannii cells pre-grown on 
carnitine. Indeed, we observed a decrease 
in TMA production in the presence of 
MMV3 and MMV12 (Figure 6C), whilst 
MMV1 did not inhibit TMA formation in 
the bacterial culture. MMV3 has almost 
completely inhibited TMA formation while 
MMV12 caused ~20% reduction in TMA 
production. It is worth mentioning that 
MMV3 was originally developed for 
treating tuberculosis and the differences in 
inhibitor activity towards A. baumannii 
cells may reflect their ability to penetrate 
bacterial cell membranes.    
 
Discussion 
A major breakthrough in gut microbiome 
research over the past decade is the 
realization that gut microbiota play an 
integral role in human health and diseases 
(48). This is exemplified in the study of 
TMA-formation from gut microbiota and 
its implication in the development of 
atherosclerosis and cardiovascular 
diseases (9-11). Recent progress using 
experimental animals and human clinical 
studies have shown that TMA precursors 
such as choline, carnitine and -
butyrobetaine promote atherosclerosis via 
the TMAO pathway through the interplay 
between gut microbiota and host 
metabolism (49). The identification of the 
key microbial enzymes, including the 
choline-TMA lyase (12) and CntA (13) 
provides promising new drug targets for 
attenuating TMA release from gut 
microbial metabolism of TMA-precursors. 
Although much has been learnt from the 
structures of choline-TMA lyase and 
subsequent development of selective 
inhibitors for choline-to-TMA 
transformation (18-21), little progress has 
been made on CntA due to the lack of CntA 
structures. Here in this study, we provide 
the structural basis of substrate co-
ordination and mode of inhibition by the 
newly discovered inhibitors. The structure 
and EPR analysis also allow us to better 
understand the structural basis of long-
range electron transfer across the 
interface of CntA subunits.   
Rieske oxygenases are challenging 
proteins to study and this was no different 
in the case of CntA. Different expression 
strategies or the choice of buffers and 
additives may have contributed to the 
apparent differences in enzyme activities 
among studies of CntA protein (13, 50). 
Due to sensitivity to oxygen, considerable 
effort was made in our work in order to 
obtain CntA crystals. It is worth noting that 
the presence of SCN in the crystallisation 
media was essential to obtain CntA 
crystals. Given that we observe the SCN 
coordinated to the Fe centre in CntA-
carnitine and CntA-gBB complex, we 
investigated the effect of additional SCN on 
the activity of CntA. Indeed, SCN inhibited 
CntA activity with the half maximal 
inhibitory concentration (IC50) of 35 mM 
(Figure S10A) and EPR analysis showed that 
the addition of SCN may have affected 
inter-/intra subunit electron transfer 
(Figure S10B). It is therefore likely that SCN 
affects CntA functionality by coordinating 
to the Fe centre and preventing oxygen 
binding, which in turn helps to stabilise the 
protein for crystallization.  
Our study shows that CntA forms a 
head-to-tail homotrimer and the 
substrates appear to be poised in place 
next to the mononuclear Fe centre ready 
for cleavage. Despite both substrates (i.e. 
carnitine and -butyrobetaine) possessing 
carboxylate moieties, these are not 
coordinated to the mononuclear Fe centre 
as might be expected and that has been 
observed for group Vb Rieske oxygenase 
such as proline-bound stachydrine 
demethylase Stc2 (28). The Y203 residue is 
strictly conserved in all CntA sequences 
which is key for a -cation interaction to 
coordinate the ammonium moiety of the 
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substrate and for a - stacking interaction 
to the inhibitor (Figure 6). This 
corresponding aromatic residue is also 
present in other group Va Rieske 
oxygenases, such as choline 
monooxygenase (tyrosine) and OxyBAC 
(phenylalanine) (Figure 4), suggesting that 
such a -cation interaction is commonly 
used for orientating choline and 
benzalkonium during catalysis. Conversely, 
when compared to the stachydrine and 
glycine betaine degrading enzymes, Stc2 
and BmoA/GbcA respectively, there is not 
an aromatic residue present in the same 
position. The structure for Stc2 showed 
that stachydrine coordinates to the 
mononuclear Fe through the carboxylate 
group and the suggested mechanism 
requires this binding mode in order to 
cleave the methyl substituent (28). This 
insight suggests a differentiation amongst 
the Group V members and thus a 
distinctive way to classify quaternary 
ammonium catalysis by such Rieske 
oxygenases. 
Among the substrate analogues 
tested for CntA, activity was only seen in 
compounds containing a quaternary 
ammonium group, In agreement with the 
pivotal role of the π-cation interaction for 
substrate coordination. Given the link 
between TMA production and 
cardiovascular diseases, targeting CntA 
with small molecule inhibitors could have a 
therapeutic potential. Inhibitors for CntA 
may also be useful to treat individuals with 
a socially challenging condition 
trimethylaminuria (TMAU) or commonly 
referred to as the “fish odour syndrome” 
(51). An elegant example of such rational 
designed inhibitors starting from the 
endogenous substrate has been reported 
for the choline-TMA lyase, CutC with DMB 
(3,3-dimethyl-1-butanol), DMBA (3,3-
dimethylbutyric aldehyde), FMC (N-
(fluoromethyl)-2-hydroxy-N,N-
dimethylethan-1-aminium) and (3S) ‐ 1 ‐
methyl‐3,6‐dihydro‐2H‐pyridin‐3‐ol (18-
21). FMC is reported as the most potent 
inhibitor with an EC50 of 56 nM by forming 
an irreversible covalent bond in the CutC 
catalytic site (20). Encouragingly and 
particularly relevant to CntA is the 
development of inhibitors based on the 
structure of -butyrobetaine against the 
carnitine-producing -butyrobetaine 
hydroxylase from human (52). The 
inhibitors were derivatives of the 
trimethylammonium, aliphatic chain and 
carboxylate region with some 
demonstrating a similar binding mode to 
the native substrate but with higher 
affinities. The structure of CntA, together 
with the information inferred from the 
substrate mimics and the competitive 
inhibitors that we reported here in this 
study, could be investigated in a rational 
drug design approach to formulate more 
potent CntA inhibitors for future 
exploitation. The data presented here 
suggest CntA substrate analogues are less 
likely to inhibit its activity and rational drug 
design should perhaps take advantage of 
the presence of several aromatic residues 
in the binding pocket to utilize a - 
stacking interaction as we have 
demonstrated in the inhibitor compound 
(Figure 6). 
Taking advantage of the CntA 
structure we solved in this study, we 
employed EPR analysis to track the 
activation and progression of the electron 
transfer pathway involving the carnitine 
oxygenase complex. We propose that 
during catalysis, CntA and its associated 
reductase, CntB approach and electron 
transfer from the one-electron reduced 
ferredoxin [2Fe-2S]+1 in CntB to the 
oxidized Rieske [2Fe-2S]2+ effectively takes 
place. Efficient electron transfer from the 
reduced Rieske [2Fe-2S]1+ centre to the 
catalytic mononuclear Fe centre in CntA 
requires both substrate, carnitine and the 
crucial bridging glutamate reside E205, 
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mutation of which significantly alters 
electron flow (Figure 2C), resulting in the 
loss of enzyme activity (Figure 2D). This 
was also independently validated by a 
recent study showing that both E205D and 
E205Q mutants lost enzyme activity and 
the ability for electron transfer to the 
active centre (13, 50). Binding of the 
substrate to the catalytic mononuclear Fe 
centre caused a shift in g3 tensor from 
3810 G to 3750 G (Figure 2C). This suggests 
that substrate entrance might influence 
the redox-potential of the mononuclear Fe 
centre in CntA, possibly influencing the 
electron transfer from the reduced Rieske 
centre to the mononuclear Fe centre in 
CntA although its impact on the one 
electron reduced Rieske centre cannot be 
completely ruled out. The terminal step of 
the electron transfer pathway is the 
formation of an organic radical species 
(Table 2) which is likely to be crucial for 
CntA catalysis. Its identity, however, has 
yet to be elucidated. Potential active 
intermediates in other well studied Rieske 
oxygenases include Fe(III)-(hydro)peroxy 
followed by a rearrangement leading to a 
high valent hydroxo-Fe(V)=O or Fe(IV)=O 
species (53-55). The active high valent 
catalytic Fe in CntA catalysis certainly 
warrants further investigations. However, 
the methodology established here may 
also facilitate the discovery of novel CntA 
inhibitors targeting the electron transfer 
pathway.  
To sum up, this work provides the 
structural basis of carnitine degradation by 
CntA. Structural determination of CntA and 
spectroscopic characterisation using EPR 
provides structural and mechanistic insight 
into the role of bridging glutamate (E205) 
in inter-subunit electron transfer. Co-
crystallisation of the substrates and the 
competitive inhibitor with CntA unveils the 
role of the π-π stacking interaction as the 
key mode of inhibition. The work 
presented here provides the structural 
basis to facilitate rational design and 
further optimization of specific inhibitors 
targeting carnitine-to-TMA transformation 
by gut microbiota.  
 
Methods 
Cloning of CntAB and site-directed 
mutagenesis of CntA. The plasmids for 
expressing CntA and CntB of A. baumannii 
were constructed previously (13). All A. 
baumannii CntA mutants were chemically 
synthesized by GenScript and cloned into 
the pET28a(+) expression vector using the 
NdeI and HindIII sites. All plasmids were 
transformed into BL21(DE3)pLysS cells for 
protein expression as described previously 
(13).  
 
Protein expression and purification. For 
each respective protein, recombinant E. 
coli strains were streaked from glycerol 
stocks onto LB agar plates with kanamycin 
(50 µg/mL) and incubated overnight at 
37°C. Recombinant protein expression was 
induced with 0.2 mM IPTG into liquid 
culture in LB medium. After 18 hours 
incubation the cells were collected by 
centrifugation at 6,000 rpm at 4°C for 10 
minutes and the pellet was resuspended in 
20mL PBS + 0.3M NaCl on ice, aliquoted 
and frozen at -80°C. For purification the 
standard buffer conditions were 20 mM 
Tris-HCl pH 7.6, 250 mM NaCl and 0.5 mM 
tris(2-carboxyethyl)-phosphine (TCEP). To 
purify CntA and CntB proteins, cells were 
broken by sonication in the standard buffer 
and the cell-free extract was loaded on a 
Roche Complete resin for affinity 
purification. The resin was then washed 
with standard buffer + 5 mM imidazole and 
the target protein was eluted with the 
standard buffer + 250 mM imidazole + 10% 
(v/v) glycerol. The elution was 
concentrated in a Vivaspin 20 10,000 kDa 
cut-off to 2.2 mL before loading onto a 
Superdex 200 16/600 column using an 
ÄKTA purifier and buffer exchanging into 
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10 mM HEPES, 250 mM NaCl, 0.5 mM TCEP 
and 10% glycerol (v/v) buffer for storage or 
10 mM HEPES pH 7.6, 10 mM NaCl and 0.5 
mM TCEP for crystal growth. For storage, 
the protein was concentrated to 2mg/mL 
in a Vivaspin 6 10,000 kDa and aliquots 
were kept frozen at -20°C, for 
crystallography the protein was 
concentrated to the desired amount 
(between 5 to 50 mg/mL) and used 
immediately in crystallisation setups. 
Purified CntB was estimated to have ~ 0.85 
FMN per CntB using the method of Batie et 
al. (1987) by measuring absorbance at 462 
nm against FMN standards ranging from 
0.3 to 321.5 µM (35). 
 
Protein crystallography. CntA crystals 
were seeded and obtained at 22°C using 
the hanging drop method. All drops 
contained 1µL of protein material and 1µL 
crystallisation condition. Initial 
crystallisation conditions were obtained 
from sparse matrix screening using JCSG-
plusTM (Molecular Dimensions) and 
optimised using the Additive Screen 
(Hampton Research). Seeding material was 
generated with protein at 10-20 mg/mL in 
drops containing 100 mM HEPES, 0.2 M 
NaSCN, 20% (w/v) PEG 3350, 10 mM NaCl 
and 0.5 mM TCEP where large irregular 
crystals formed over 48 hours at 22°C. 
These crystals were scratched with 
acupuncture needles and then streaked 
through drops containing protein at 7.5 
mg/mL 100 mM HEPES, 0.2 M NaSCN, 18% 
(w/v) PEG 3350, 10 mM NaCl and 0.5 mM 
TCEP with substrates (carnitine and -
butyrobetaine) also present at a final 
concentration of 1 mM, the needle was run 
through 2 consecutive drops with a third 
drop on the cover slip as a control. Single 
red hexagonal crystals developed between 
24 and 36 hours at 22°C and were collected 
immediately thereafter (prolonged 
incubation of the crystals was found to be 
detrimental to their crystal quality). 
Crystals were cryoprotected in an 
equivalent solution to the mother liquor 
supplemented with 5% glycerol and flash 
cooled in liquid nitrogen. For 
CntA+MMV020670, MMV020670 was 
added to a final concentration of 250 µM 
in the crystallisation condition buffer drops 
that were streaked and yielded the same 
red hexagonal crystals 36-48 hours after 
setting up. The crystals were collected and 
stored as mentioned above. 
 
The crystals were mounted robotically on 
the i24 beamline (apo, carnitine and -
butyrobetaine) and i04 beamline 
(CntA+MMV020670) at the Diamond Light 
Source (Harwell Science and Innovation 
Campus, Didcot, UK). In the apo and -
butyrobetaine collections, we observed 
split spots and streaking of spots on some 
images. The apo, carnitine and 
MMV020670 data were auto-processed 
with Dials (56) using the Xia2 pipeline at 
Diamond Light Source followed by scaling 
with Aimless (57). For the -butyrobetaine 
dataset we processed the data using the 
Dials User Interface (DUI) followed by 
scaling with Aimless in the CCP4i2 suite of 
tools (58). An initial model was derived 
from PDB 3VCP. Molecular replacement 
was performed in PHASER. Autobuilding in 
phenix.autobuild was followed by  iterative 
rounds of manual building in COOT (59) 
interspersed with refinement  in PHENIX 
(60). Within Coot, monomers for L-
carnitine (PDB code 152), -butyrobetaine 
(PDB code NM2), glycerol (GOL), 
thiocyanate (SCN) and HEPES (EPE) were 
added into clear density that was evident 
in both 2fo-fc and fo-fc maps consistent 
with the respective ligands. In order to 
assign the coordinates for MMV020670, 
Polder OMIT maps (61) were generated in 
PHENIX. Geometry restraint information as 
.cif file for MMV020670 was generated in 
eLBOW (62) within the PHENIX suite of 
programmes and the MMV020670 
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inhibitor was added into the model guided 
by Polder OMIT maps. The structure model 
coordinates can be accessed from the PDB 
repository with the following accession 
codes: CntA Apo (6Y8J), CntA + carnitine 
(6Y9D), CntA + gBB (6Y8S) and 
CntA+MMV020670 (6ZGP). 
 
UV/VIS Enzyme assays. All activity assays 
were performed on a BMG FLOUstar 
Omega 96 well plate reader, set at 
wavelength 340 nm with a sample volume 
of 200 µL. The assay comprised of 
combining mixture A 60 µg CntA and 60 µg 
CntB with mixture B 0.25 mM L-carnitine 
and 0.25 mM NADH in a 10 mM HEPES 
buffer, pH 7.6 with 250 mM NaCl and 0.5 
mM TCEP. The enzyme does not accept 
NADPH as the electron donor and the 
additional flavin (FAD or FMN) to the 
enzyme assay mixture had no major impact 
on enzyme activities (Figure S1). The 
reactions were measured for 5 minutes 
recording the linear decrease of signal at 
340 nm for NADH oxidation. The slope of 
the line was measured between 60 and 
120 seconds to yield the rate.  
 
Michaelis–Menten kinetics. Michaelis–
Menten kinetic parameters were derived 
using the UV/VIS Enzyme assays 
methodology above. Substrate 
concentrations were varied from a top 
concentration of 2 mM and decreasing in a 
2-fold manner for 10 successive dilutions. 
Observed rates were obtained from 4 
independent measurements and fitted to a 
nonlinear regression Michaelis-Menten 
model in Prism 8 for macOS v8.2.0. 
 
Electron Paramagnetic Resonance (EPR) 
analysis. EPR measurements were carried 
out using a Bruker ELEXSYS-500/580 X-
band EPR spectrometer operating in both 
continuous-wave (cw) and pulsed modes, 
equipped with an Oxford variable-
temperature unit and ESR900 cryostat with 
Super High-Q resonator as reported 
previously (63-64). All EPR samples were 
prepared in the quartz capillary tubes 
(outer diameter; 4.0 mm, inner diameter 
3.0 mm) and flash-frozen immediately and 
stored in liquid N2 until analysis. The X-
band EPR tubes were then transferred into 
the EPR probehead, which was pre-cooled 
to 20 K. The low-temperature EPR spectra 
were measured at 20 K as a frozen 
solution. A microwave power of 30 dB (0.2 
mW) and modulation of 5 G appear to be 
optimal for recording the EPR spectrum of 
the CntA/CntB (oxygenase/reductase) 
domains prepared under various 
experimental conditions. The 
concentration of the CntA/CntB domains 
was 200 μM in all the samples.  All 
experiments were carried out in 10 mM 
HEPES, pH 7.6, 250 mM NaCl, 10 % Glycerol 
and 0.5 mM TCEP, with additional NADH 
and or L-carnitine at a final concentration 
of 75 mM added accordingly. The analysis 
of the cw-EPR spectra and simulations 
were performed using EasySpin toolbox 
(5.2.18) for the Matlab program package 
(65). 
 
Circular Dichroism. The proteins were 
buffer exchanged on a PD-10 column into a 
0.2M sodium phosphate buffer with 0.01M 
NaCl at pH 7.0 and prepared at 0.1mg/mL 
final concentration. The samples were 
analysed on a JASCO J-1500 at 20°C using a 
0.1mm path length quartz cuvette. Data 
was collected between 260 to 180 nm with 
8 scans per sample collected.  
 
Inhibitor screening assay. Compounds in 
the Pathogen Box 
(https://www.mmv.org/mmv-
open/pathogen-box/about-pathogen-box) 
were received as 10 mM stocks dissolved 
in dimethylsulfoxide (DMSO). The 
compounds were added such that the final 
concentration was 50 µM in the 200 µL 
reaction. As per the “UV/VIS Enzyme 
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assays” methodology above, the protein in 
mixture A was incubated with inhibitor 
compounds for 20 minutes before 
commencing the assay. Compounds that 
demonstrated 25% or better inhibition 
relative to an untreated and equivalent 
DMSO control were further validated in 
two successive independent assays to 
confirm the inhibition activity to CntA. 
 
Inhibitory IC50 determination. From a 25 
mM stock solution of compound material 
dissolved in DMSO, a 3-fold, 10 step serial 
dilution was prepared and the final 
concentration of each compound ranges 
from 300 µM to 0.015 µM. The assay was 
carried out as per the “UV/VIS Enzyme 
assays” and “Inhibitor screening” 
methodology above and each compound 
was incubated with the protein material 
for 20 minutes prior to assaying. For each 
concentration, 4 replicates were carried 
out. IC50 values were determined using a 
built-in “Dose Response Inhibition” – 
[Inhibitor] vs. response model in Prism 8 
for macOS v8.2.0. 
 
Inhibitor Competition assays. As per the 
Michaelis Menton kinetics methodology 
above, we carried a series of 4 runs in the 
presence of (i) 0x (control), (ii)0.25x, (iii)1x 
and (iv)4x of the IC50 value for each 
inhibitor compound with 4 independent 
replicates for each run and fitted to a 
nonlinear regression Michaelis-Menten 
model in Prism 8 for macOS v8.2.0. 
 
Evaluation of inhibitors in A. baumannii 
cell culture. A. baumannii cells were 
cultured overnight in the M9 minimal 
media at 37°C with 10 mM L-carnitine as 
the sole carbon source. The cells were then 
collected by centrifugation and washed 
twice in a buffer containing 10 mM HEPES, 
1 mM NaCl (pH 7.6). After wash, the cells 
were resuspended in the same buffer to a 
density of OD600 of 0.4. The cells were 
aliquoted into 5mL per replicate and 
carnitine was added to a final 
concentration of 1 mM with/without the 
addition of the inhibitors (i.e. MMV1, 
MMV3 and MMV12) at a concentration of 
200 µM. A corresponding DMSO only 
control was also included. These cells with 
appropriate treatments were incubated at 
37°C for 1 hour. The supernatant was then 
obtained by filtering through a 0.2 µm filter 
and analysed by ion chromatography by 
quantifying TMA production and carnitine 
degradation as described previously (13).  
 
Chemical structures and protein structure 
depictions. MarvinSketch was used for 
drawing, displaying and characterizing 
chemical structures (Marvin v19.10.0 for 
Mac, 2019, ChemAxon 
http://www.chemaxon.com). Reaction 
summaries were drawn in ChemDraw 
V17.0 for Mac. Molecular graphics and 
analyses were performed with UCSF 
Chimera (66), Chimera X (67) and Coot 
(59). Protein-ligand interaction maps were 
generated in Maestro (Academic) 
v11.9.010 Release 2019-1 – Schrodinger. 
 
in silico docking. Structures were prepared 
in MarvinSketch, saved as .sdf files an 
imported in to Flare (Cresset) (v3.0). The 
CntA+MMV020670 pdb file was imported 
into Flare and minimised using the 
standard built-in protocols. The ligands 
were docked using the built-in docking 
engine using the MMV020670 ligand pose 
as a template.  
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Table 1 X-ray data collection and refinement statistics. 
 
Name CntA Apo CntA + Carnitine CntA + gBB CntA+MMV12 
PDB code 6Y8J 6Y8S 6Y9D 6ZGP 
Wavelength (Å) 
1.7 1.3 1.3 0.9 
Resolution range (Å) 
40.1  - 2.05  
(2.12  - 2.05) 
81.42  - 1.97  
(2.04  - 1.97) 
39.78  - 1.63  
(1.69  - 1.63) 
78.64  - 2.01  
(2.08  - 2.01) 
Space group 
P 63 P 1 21 1 P 63 P 1 21 1 
Unit cell 
91.6 91.6 82.96 
90 90 120 
91.59 177.77 158.8 
90 90.17 90 
91.16 91.16 81.47 
90 90 120 
91.07 173.77 157.29 90 
90.15 90 
Total reflections 
224999 (13603) 1180725 (105398) 203443 (9804) 2229436 (218489) 
Unique reflections 
24714 (2443) 353116 (35196) 47465 (4434) 322879 (32095) 
Multiplicity 
9.1 (5.6) 3.3 (3.0) 4.3 (2.2) 6.9 (6.8) 
Completeness (%) 
99.3 (99.2) 98.8 (98.4) 98.8 (93.4) 99.4 (99.1) 
Mean I/sigma(I) 
7.41 (1.14) 5.2 (1.21) 6.8 (1.13) 6.9 (1.13) 
Wilson B-factor (Å2) 
38 31 24 33 
R-merge 
0.189 (1.429) 0.149 (0.958) 0.134 (0.755) 0.165 (1.783) 
R-meas 
0.200 (1.575) 0.178 (1.168) 0.152 (0.967) 0.179 (1.929) 
R-pim 
0.064 (0.651) 0.096 (0.660) 0.070 (0.595) 0.068 (0.733) 
CC1/2 
0.994 (0.438) 0.984 (0.638) 0.982 (0.517) 0.996 (0.698) 
CC* 
0.999 (0.781) 0.996 (0.883) 0.996 (0.825) 0.999 (0.907) 
Reflections used in 
refinement 
24704 (2441) 352719 (35160) 47464 (4434) 321994 (31973) 
Reflections used for R-
free 
1223 (101) 17582 (1828) 2374 (221) 16243 (1504) 
R-work 
0.201 (0.429) 0.207 (0.338) 0.1704 (0.323) 0.216 (0.386) 
R-free 
0.248 (0.530) 0.243 (0.371) 0.193 (0.339) 0.254 (0.421) 
CC(work) 
0.958 (0.737) 0.961 (0.805) 0.963 (0.726) 0.961 (0.799) 
CC(free) 
0.942 (0.821) 0.953 (0.760) 0.911 (0.768) 0.948 (0.736) 
Number of non-
hydrogen atoms 
2874 35752 3117 36701 
macromolecules 
2803 34344 2832 34901 
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ligands 
4 408 31 588 
solvent 
67 1000 254 1212 
Protein residues 
345 4224 350 4328 
RMS(bonds) (Å) 
0.008 0.009 0.007 0.009 
RMS(angles) (°) 
1.18 1.10 1.05 1.32 
Ramachandran favored 
(%) 
94.67 95.35 95.91 94.76 
Ramachandran allowed 
(%) 
5.33 4.50 3.80 4.98 
Ramachandran outliers 
(%) 
0.00 0.14 0.29 0.26 
Rotamer outliers (%) 
0.00 0.87 0.00 0.85 
Clashscore 
5.86 9.36 3.41 13.20 
Average B-factor (Å2) 
55.95 45.44 35.71 51.59 
Macromolecules (Å2) 
56.24 45.40 34.94 51.60 
[2Fe-2S] Rieske 
Centre 
44.74 41.35 25.56 48.08 
Fe 
N/A 45.15 176.41 56.77 
Substrate 
N/A 47.02 57.75 N/A 
Inhibitor 
N/A N/A N/A 69.75 
Solvent (Å2) 
44.69 39.21 42.61 44.22 
Number of TLS groups 
9 48 10 44 
 
  
 by guest on N
ovem
ber 10, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 22 
Table 2 Spin-Hamiltonian parameters used to model the EPR spectra. 
 
A This EPR active signal may also contain an overlapping EPR-signals derived from the catalytic mononuclear iron centre; plausible EPR active 
intermediates are ferric-(hydro)peroxy or a high-valent iron(V)-oxo species.  
 
B This may represent an overlay of both a flavin and an unidentified organic radical. 
  
Samples EPR active signal species  % g1 g2 g3 gave 
As-isolated CntA 
 
   2.0105 1.9157 1.7574 1.8945 
         
As-isolated CntB No EPR active signal detected     
      
CntB+NADH [2Fe-2S]+1  specA (reduced ferredoxin domain)   93 2.0314 1.9372 1.8988 1.9558 
Flavin radical   specB (Flavin radical)  7 2.0015 2.0015 2.0015 2.0015 
         
CntA+CntB+NADH [2Fe-2S]+1 in CntB specA (reduced ferredoxin domain)  61 2.0313 1.9376 1.8979 1.9556 
 Flavin radical specB  2 2.0010 2.0034 2.0039 2.0028 
 [2Fe-2S]+1 in CntA specC (reduced Rieske centre)  37 2.0079 1.9153 1.7542 1.8924 
 
CntA+CntB+NADH+Carnitine 
        
an organic radical   specB  34 2.0000 2.0035 2.0037 2.0024 
[2Fe-2S]+1 in CntA A  specC  66 2.0071 1.9077 1.7986 1.9045 
         
E205A+CntB+NADH+Carnitine 
 
[2Fe-2S]+1 in CntB  specA1  40 2.0338 1.9397 1.8868 1.9534 
[2Fe-2S]+1 in CntB  specA2  20 2.0449 1.9493 1.9037 1.9660 
Flavin radical B  specB  8 2.0012 2.0040 2.0040 2.0031 
[2Fe-2S]+1 in CntA A  specC  32 2.0070 1.9077 1.7896 1.9014 
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Figure 1 The overall structure of CntA and its catalytic centre. 
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A, The reaction of carnitine oxidation by CntAB to trimethylamine (TMA) and malic 
semialdehyde. 
B, CntA depicted as a homotrimer with the secondary structure represented in a ribbon 
depiction in a translucent overall surface representation with each monomer in blue, red 
and green, respectively.  
C, An overlap of three monomer structure units (apo, carnitine-bound, gBB-bound), showing 
no major changes to the tertiary structure of CntA with and without ligands bound. The C 
and N labels refer to the sequence termini. The Rieske centre and the mononuclear Fe 
centre are 44 Å apart in the same subunit.  
D, The Rieske centre in CntA is coordinated by Cys86, Cys106, His88 and His109. 
E, The catalytic mononuclear Fe centre in CntA is coordinated by a His-His-Asp catalytic triad 
(His208, His213, Asp323), a water and thiocyanate ion. Carnitine is shown above the 
mononuclear Fe centre with a distance from the water molecule to the site of substrate 
cleavage.  
F, Electron paramagnetic resonance (EPR) spectra of as isolated CntA in the presence of nitric 
oxide (NO), showing the EPR-active, S = ½ species due to the formation of Fe2+-NO adduct.; 
EPR conditions; microwave power 30 dB, modulation amplitude 5 G, time constant 81 ms, 
conversion time 41 ms, sweep time 84 s, receiver gain 60 dB, average microwave frequency 
9.384 GHz, temperature 20 K. 
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Figure 2 Structural basis of inter-subunit electron transfer and investigations by EPR.   
A, Electron transfer in CntA between the Rieske centre and the mononuclear Fe centre across 
the interface of two neighbouring CntA subunits (coloured in cyan and brown, 
respectively) involved a key bridging glutamate reside (E205). Distances shown in Å.  
B, Proposed electron transfer pathways from the reductant NADH to the catalytic 
mononuclear Fe centre in CntA via the reductase CntB.  
C, EPR spectra of a series of combinations of WT CntAB proteins, E205A mutant, NADH and L-
carnitine to track the propagation of EPR signal and thus the inter/intra subunit electron 
transfer. NADH reduction in CntB (black trace to red trace; steps 2 and 3 in Fig. 2B); the 
EPR active [2Fe-2S]+1 species in the CntA Rieske centre with and without carnitine present 
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(red trace to magenta trace and cyan trace; steps 4-6 in Fig. 2B). The E205A mutant (wine 
red trace) demonstrates an EPR signal different to that of the wild-type CntA (cyan trace), 
indicating a disruption to the electron transfer pathway; EPR conditions; as in Fig 1E. 
D, Activity assays of CntA E205 mutants. 
E, Circular dichroism measurement comparisons between CntA wild type and E205 mutant 
enzymes showing no difference in secondary structure. 
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Figure 3 CntA substrate binding pocket. 
A, Michaelis-Menten kinetics of CntA (n=4).  
B, 2mFo − DFc map at 1.5 maps (Blue) of carnitine displayed at 3.0 and -butyrobetaine 
(gBB) displayed at 2.5. 
C, Carnitine and -butyrobetaine interacting residues in the active site amongst which Y203 
interacts with the substrate of CntA through the π-cation interaction.  
D, Enzyme activity of site-directed mutants of key residues involved in substrate coordination 
in CntA from N=3 independent replicates. The Y203F mutant in CntA regains activity 
alluding to the crucial role of the aromatic system for a π-cation interaction.  
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Figure 4 CntA represents a novel group of Rieske oxygenases using quaternary amine 
substrates (group V).  
A, Phylogeny of Rieske oxygenases showing the five distinct groups. The evolutionary history 
of Rieske oxygenases was inferred using the Neighbour-Joining method in MEGA7 (68). 
The dashed circle grouping shows the clustering of CntA including Acinetobacter 
baumannii (Ab), Escherichia coli SE11 (Ec), Klebsiella pneumonia (Kb) and Citrobacter 
freundii (Cf) (See supplementary information, Appendix 1 for a list of gene accession ID’s). 
Group V Rieske oxygenases oxidise quaternary amine substrates, including carnitine 
(CntA), choline (CmoA/B/C), benzalkonium (OxyBAC), glycine betaine (BmoA, GbcA) and 
stachydrine (Stc2).  
B, Chemical reactions catalysed by Rieske enzymes from the Group V Rieske oxygenases 
involved in quaternary amine oxidations. Group Va includes carnitine oxygenase (CntA) 
choline monooxygenase (CmoA, CmoS and CmoB) and benzalkonium oxygenase (OxyBAC). 
Group Vb carries out oxidative demethylation reactions.  
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C, Sequence alignment of the substrate binding pocket residues of group V Rieske oxygenase 
involved in quaternary amine oxidation. The aromatic residues for substrate coordination 
through a π-cation in group Va and the corresponding position in group Vb are 
highlighted by a red arrow. The Rieske centre is coded in blue, the catalytic triad of the 
mononuclear Fe centre is shown in purple and the bridging carboxylate is highlighted in 
pink. 
D, The substrate binding site of the group Vb quaternary amine degrading enzyme Stc2. The 
substrate mimic proline in Stc2 coordinates with the catalytic mononuclear Fe centre via 
a carboxylic acid group.   
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Figure 5 Structure activity relationship of CntA substrate profiling and coordination during 
catalysis.  
A: A structure activity relationship scaffold hopping map of substrate analogues tested with 
a single change between structures and the progression shown with arrows. Structures 
in blue represent active substrates, whilst those in red are inactive. (1) Carnitine, (2) g-
BB, (3) Meldonium, (4) (1-Butyl)Trimethylammonium, (5) (1-Hexyl)Trimethylammonium, 
(6) (1-Octyl)Trimethylammonium, (7) (Cyclopropylmethyl)-Trimethylammonium, (8) (3-
Hydroxypropyl)Trimethylammonium, (9) (3-Oxobutyl)Trimethylammonium, (10) 4-
(Dimethylamino)butyric acid, (11) 4-(Methylamino)butyric acid and (12) gamma-
Aminobutyric acid. 
B, The coordination of quaternary amine substrates in the CntA binding site during catalysis 
showing the role played by Tyr 203 and Tyr 295 in coordinating the substrates. 
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Figure 6 Structural basis of CntA inhibition 
A, Chemical structures of the three CntA inhibitors : (MMV1) = MMV010764 (N‐[(oxan‐4‐
yl)methyl]‐5‐ (thiophen‐2‐yl)imidazo[2,1‐b][1,3,4]thiadiazol‐2‐amine), (MMV3) = 
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MMV661713(6 ‐ (5 ‐ bromopyridin ‐ 3 ‐ yl) ‐N ‐ [3 ‐ (1H ‐ imidazol ‐ 1 ‐ yl)propyl] ‐ 2 ‐
phenylpyrimidin‐4‐amine) and (MMV12) = MMV020670 (N‐ [3‐ (1H‐ imidazol‐1‐
yl)propyl]‐8‐methyl‐1,6‐naphthyridine‐2‐carboxamide). 
B, A summary of the inhibitor assays with inhibitory IC50 data values shown for n = 3 replicates. 
C, Evaluation of CntA protein inhibitors (MMV1, MMV3, MMV12) using A. baumannii bacterial 
cultures. Cells treated with inhibitors MMV3 (p<0.0001) and MMV12 (p<0.001) caused 
significant reduction in TMA formation from carnitine whereas MMV1 did not reduce 
TMA production. Carnitine was added to a final concentration of 1 mM prior to the 
incubations with/without additional inhibitors. Control runs of buffer only and DMSO 
only did not have carnitine in the treatment and no TMA was observed. N=3 for all 
conditions. Statistics was carried out using one-way ANOVA.  **, p<0.01; ***, p<0.001; 
****, p<0.0001. 
D, A Polder OMIT map (Blue) of MMV12 (MMV020670) displayed at 3.0 in the CntA active 
site.  
E & F, A comparison of selected residues in the CntA active interacting with the carnitine 
substrate and MMV12 (MMV020670) inhibitor. Polar interacting residues (Magenta) remain 
unchanged whilst for the hydrophobic π-π interacting residues (Dark Grey), positional 
changes for Phe 258 and Phe 216 as indicated by dashed arrows in panel E. 
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